Literature DB >> 20653781

Differential gene expression in classic giant cell tumours of bone: Tenascin C as biological risk factor for local relapses and metastases.

Laura Pazzaglia1, Amalia Conti, Antonella Chiechi, Chiara Novello, Giovanna Magagnoli, Annalisa Astolfi, Andrea Pession, Tibor Krenacs, Marco Alberghini, Piero Picci, Maria Serena Benassi.   

Abstract

AIMS: To identify candidate prognostic biological markers useful in selecting high-risk patients with classic primary giant cell tumours (GCT). GCT specimens with different behaviour associated with an increased risk of local and/or distant relapses were studied. METHODS AND
RESULTS: Screening mRNA microarray analysis followed by real-time polymerase chain reaction and immunohistochemistry on tissue microarray sections was used to validate the prognostic role of differentially expressed genes on a larger series by statistical analysis tests. Global gene expression profiling identified 109 differentially expressed genes according to prognosis. A correlation was found between mRNA levels and clinical outcome identifying Tenascin C (TNC) as the most significant prognostic biological marker. By means of backward Wald logistic regression, TNC overexpression defined an eightfold increased risk for metastasis and fourfold for local recurrence. At the protein level, TNC immunoreactivity resulted in a significant difference in the disease-free survival probability curves, providing a stratification for GCT patients, useful for predicting relapse.
CONCLUSIONS: Our study provides important data for the selection of biomarkers with a significant clinical impact and suggests the importance of TNC expression in identifying GCT patients at a higher risk of relapse for closer follow-up and adjuvant medical therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20653781     DOI: 10.1111/j.1365-2559.2010.03597.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  Regulation of tenascin expression in bone.

Authors:  Jessica M Morgan; Alice Wong; Clare E Yellowley; Damian C Genetos
Journal:  J Cell Biochem       Date:  2011-11       Impact factor: 4.429

Review 2.  Prognosis of local recurrence in giant cell tumour of bone: what can we do?

Authors:  Yifeng He; Ji Zhang; Xiaoyi Ding
Journal:  Radiol Med       Date:  2017-03-07       Impact factor: 3.469

3.  p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1.

Authors:  Taketo Okubo; Tsuyoshi Saito; Hiroyuki Mitomi; Tatsuya Takagi; Tomoaki Torigoe; Yoshiyuki Suehara; Kazuo Kaneko; Takashi Yao
Journal:  Virchows Arch       Date:  2013-06-08       Impact factor: 4.064

4.  Tartrate-Resistant Acid Phosphatase 5b is a Useful Serum Marker for Diagnosis and Recurrence Detection of Giant Cell Tumor of Bone.

Authors:  Tetsuya Shinozaki; Kenichi Saito; Tsutomu Kobayashi; Takashi Yanagawa; Kenji Takagishi
Journal:  Open Orthop J       Date:  2012-09-03

5.  Differential Expression of ADAM23, CDKN2A (P16), MMP14 and VIM Associated with Giant Cell Tumor of Bone.

Authors:  André Luis Giacometti Conceição; Erica Babeto; Natalia Maria Candido; Fernanda Craveiro Franco; Débora Aparecida Pires de Campos Zuccari; Jane Lopes Bonilha; José Antônio Cordeiro; Marilia Freitas Calmon; Paula Rahal
Journal:  J Cancer       Date:  2015-05-23       Impact factor: 4.207

Review 6.  How do tenascins influence the birth and life of a malignant cell?

Authors:  Florence Brellier; Ruth Chiquet-Ehrismann
Journal:  J Cell Mol Med       Date:  2012-01       Impact factor: 5.310

7.  mTOR signal transduction pathways contribute to TN-C FNIII A1 overexpression by mechanical stress in osteosarcoma cells.

Authors:  Lianhe Zheng; Dianzhong Zhang; Yunfei Zhang; Yanhua Wen; Yucai Wang
Journal:  Mol Cells       Date:  2014-02-19       Impact factor: 5.034

Review 8.  The identification of H3F3A mutation in giant cell tumour of the clivus and the histological diagnostic algorithm of other clival lesions permit the differential diagnosis in this location.

Authors:  Federica Scotto di Carlo; Giuseppina Divisato; Maurizio Iacoangeli; Teresa Esposito; Fernando Gianfrancesco
Journal:  BMC Cancer       Date:  2018-04-02       Impact factor: 4.430

9.  The distinct clinical features of giant cell tumor of bone in pagetic and non-pagetic patients are associated with genetic, biochemical and histological differences.

Authors:  Giuseppina Divisato; Federica Scotto di Carlo; Laura Pazzaglia; Riccardo Rizzo; Domenico A Coviello; Maria Serena Benassi; Piero Picci; Teresa Esposito; Fernando Gianfrancesco
Journal:  Oncotarget       Date:  2017-06-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.